10x Genomics Inc - Ordinary Shares - Class A
TXG
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.1B
Close$
$14.68
79.5% downside
Current Fair Value
79.5% downsideOvervalued by 79.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $9.10 Billion |
|---|---|
| Enterprise Value | $8.70 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.35 |
| Beta | 1.99 |
| Outstanding Shares | 129,984,169 |
Return
| Return on Equity | -9.10% |
|---|---|
| Return on Assets | -7.29% |
| Return on Invested Capital | -9.60% |
Valuation & Multiples
| P/E Ratio | -118.41 |
|---|---|
| PEG | 77.94 |
| Price to Sales | 17.89 |
| Price to Book Ratio | 11.93 |
| Enterprise Value to Revenue | 14.11 |
| Enterprise Value to EBIT | -99.48 |
| Enterprise Value to Net Income | -116 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.12 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.24
Average shareholder expectationRevenue Estimate
$146.67 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.27
Average shareholder expectationRevenue Estimate
$147.96 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 16.53% |
|---|---|
| Total Calls | 200▼ 99.97% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.39%▼ 100.63% |
|---|---|
| Total Invested | $42.72M▼ 99.14% |
| Investors Holding | 38▼ 366.00% |
ESG Score
No data
About 10x Genomics Inc
CEO: Serge Saxonov